

Power that kills the
infection causing bacteria

Xilcef[®]
Cefadroxil
जिलसेफ

E. Coli, P. Mirabilis, and Klebsiella species.

Staphylococci and/or Streptococci.

Group A beta-hemolytic Streptococci



Clinical Facts

Pharyngitis


Group A beta-hemolytic *Streptococcus* (GABHS) Pharyngitis remains a fairly common problem for family physicians. While twice daily dosing is acceptable in adults once daily dosing would be much easier and would probably lead to better compliance. The FDA currently also approved Cefadroxil among others for once daily dosing in the treatment of GABHS pharyngitis.

Gilbert DN, Moellering RC Jr, Sande MA. The Sanford Guide to Antimicrobial Therapy 1998, 28th ed.

Pharmacokinetic

Although values for the peak concentrations (C_{max}) for Cefadroxil were lower than that of Cephalexin, the levels of Cefadroxil in plasma and urine remained above the reported minimum inhibitory concentrations of susceptible organisms for longer period of time than those of Cephalexin. The elimination half-life (t_{1/2}) of Cefadroxil (about 2 h) was significantly longer than that of Cephalexin (about 1 h).

A pharmacokinetic comparison of Cefadroxil and Cephalexin after administration of 250, 500 and 1000 mg solution doses. Biopharm Drug Dispos 1996 May;17(4):319-30



Concentrations of Cefadroxil and Cephalexin in Skin Blister fluid and blood after the oral administration of 1000mg of each antibiotic.

Skin and Skin-Structure

The overall results from this retrospective study suggest that Cefadroxil is an effective agent with a favorable safety profile for the treatment of Skin and Skin-Structure infections of the foot.

Gerard V. Yu, D.P.M., F.A.C.F.A.S.,
David C. Nowicki, D.R.M., F.A.C.F.A.S.
Cefadroxil in Skin and Skin- Structure
Foot Infections: A Retrospective Review
Volume 12 No.1 January/February 1995
Pgs. 1-10.

Features

- ▼ Good GI absorption with or without food and milk.
- ▼ Effective therapy when given once or twice daily.

Thomas N. Nolen, *Modern Medicine*
1989;57 (suppl. A):56-65.

Cefadroxil is the 1st
Generation Cephalosporin

One Alternative, Cost-Effective
and Patient Compliant
Antibiotic Therapy.

**Xilcef[®]-250**
Cefadroxil 250mg Cap.

**Xilcef[®]-500**
Cefadroxil 500mg Cap.

**Xilcef[®]**
Cefadroxil for oral susp.

Indication

- ▼ Urinary Tract Infections, including Bladder infections.
- ▼ Skin Infections like Cellulitis, Furunculosis, Impetigo.
- ▼ Sore Throat, including Strep Throat or infected Tonsils.
- ▼ Bone Infections, Wound Infections, Osteomyelitis, Septic Arthritis.

Cefadroxil

Clinical Facts



Excellent Efficacious Alternative

Cefadroxil (Xilcef) is one of the most widely used first-generation cephalosporins, specially for group A beta hemolytic Streptococci. Cefadroxil (Xilcef) has excellent activity against gram-positive bacteria and would be the class of choice, if a cephalosporin is needed. It is utilized in patients with penicillin allergies where erythromycin is not used. Though, Cefadroxil & Cephalexin are equally efficacious, once daily dose of Cefadroxil will have enhance patient compliance compared to Cephalexin with dosed at 30mg/kg/day in twice or thrice daily schedule.

Adapted from: What Is the Recommended Treatment for Bacterial Tonsillitis? Wendy L. Wright, MS, RN, ARNP, FNP, 02/27/01

PRESENTATION

Each XILCEF-250 Capsule contains Cefadroxil USP equivalent to Anhydrous Cefadroxil 250mg supplied in a blister pack of 10 x 10 Capsules, Each XILCEF-500 Capsule contains Cefadroxil USP equivalent to Anhydrous Cefadroxil 500mg supplied in a blister pack of 10 x 10 Capsules. Each 5mL of the reconstituted XILCEF Suspension contains Cefadroxil USP equivalent to Anhydrous Cefadroxil 125mg supplied in 15g/ 30mL.



NOTE: Culture and susceptibility tests should be initiated prior to and during therapy. Renal function studies should be performed when indicated.

Infection	Xilcef 500 Capsule
Skin/Skin structure	1 cap BID
Pharyngitis/-Tonsillitis	2 cap OD or 1 cap BID
Cystitis	1 cap BID
Complicated UTI	2 cap BID

CHILDREN DOSING SCHEDULE

Weight	Xilcef Susp. 125mg/5mL
4.5Kg	2.5ml BID
9.1Kg	5mL BID
Upto 18.2Kg	10mL BID

For further information, please contact :
Deurali-Janta Pharmaceuticals Pvt. Ltd.
Corporate & Sales Office:
Hattisar, Kamalpokhari
GPO Box 4239, Kathmandu, Nepal.
Tel: 435167/68/69
Fax: +977-1-435166 , 412292
Email: djpl@ccsl.com.np

In Technical Collaboration with:
RENATA LIMITED
Bangladesh
® Registered Trade Mark